How to manage waldenström’s macroglobulinemia in 2024
- 5 March 2024
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 125, 102715
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- CAR T‐cell therapy in large B cell lymphomaHematological Oncology, 2023
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyThe Lancet Oncology, 2022
- Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphomaThe Lancet Oncology, 2022
- CXCR4 in Waldenström’s Macroglobulinema: chances and challengesLeukemia, 2020
- Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 studyThe Lancet Haematology, 2020
- Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain AmyloidosisTransplantation and Cellular Therapy, 2019
- High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström MacroglobulinemiaHematology/Oncology Clinics of North America, 2018
- Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundAmerican Journal of Hematology, 2018
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- How to manage Waldenstrom’s macroglobulinemiaLeukemia, 2013